{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:42:44Z","timestamp":1772239364065,"version":"3.50.1"},"reference-count":37,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T00:00:00Z","timestamp":1486944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.2217\/fmb-2016-0231","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T06:47:17Z","timestamp":1486968437000},"page":"515-525","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["The Cost of Treating Mucormycosis with Isavuconazole Compared with Standard Therapy in the UK"],"prefix":"10.1080","volume":"12","author":[{"given":"Emma","family":"Bagshaw","sequence":"first","affiliation":[{"name":"Covance Market Access, Covance, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kuessner","sequence":"additional","affiliation":[{"name":"Global Market Access and Health Economics, Basilea Pharmaceutica International Ltd, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Posthumus","sequence":"additional","affiliation":[{"name":"Global Market Access and Health Economics, Basilea Pharmaceutica International Ltd, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Escrig","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Basilea Pharmaceutica International Ltd, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Blackney","sequence":"additional","affiliation":[{"name":"Covance Market Access, Covance, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian Marcel","family":"Heimann","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver Andreas","family":"Cornely","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany"},{"name":"Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Clinical Trials Centre Cologne (ZKS K\u00f6ln), University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,2,13]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/590004"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03456.x"},{"key":"e_1_3_2_5_1","unstructured":"European Medicines Agency . Committee for Orphan Medicinal Products. Public summary of opinion on orphan designation. Isavuconazonium sulfate for the treatment of invasive aspergillosis (2014). www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2014\/07\/WC500169890.pdf"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-2023-z"},{"key":"e_1_3_2_7_1","first-page":"27","volume-title":"23rd European Congress of Clinical Microbiology and Infectious Diseases","author":"Chakrabarti A","year":"2013","unstructured":"Chakrabarti A , SoodP, DenningD. Estimating fungal infection burden in India using computational models: mucormycosis burden as a case study.Presented at : 23rd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany, 27\u201330April 2013."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2007.140087"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-310"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03908.x"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir880"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12474"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir866"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku506"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802326001"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12371"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/319211"},{"key":"e_1_3_2_18_1","unstructured":"AmBisome 50 mg powder for solution for infusion (liposomal amphotericin B). Summary of product characteristics. Gilead Sciences Ltd. (2015). www.medicines.org.uk\/emc\/medicine\/1236."},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/514341"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv236"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12203"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2012.711741"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1185361"},{"key":"e_1_3_2_24_1","unstructured":"Basilea Pharmaceutica International Ltd . Cresemba 200 mg powder for concentrate for solution for infusion. Summary of product characteristics. (2016). www.medicines.org.uk\/emc\/medicine\/31236."},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00071-2"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_3_2_27_1","unstructured":"Inflation.eu . Inflation Great Britain (2016). http:\/\/inflation.eu\/inflation-rates\/great-britain\/inflation-great-britain.aspx"},{"key":"e_1_3_2_28_1","unstructured":"Noxafil 100 mg gastro-resistant tablets (posaconazole) . Summary of product characteristics.Merck Sharp & Dohme Ltd . (2015). www.medicines.org.uk\/emc\/medicine\/28880"},{"key":"e_1_3_2_29_1","unstructured":"National Institute for Health and Care Excellence. British National Formulary (2016). www.evidence.nhs.uk\/formulary\/bnf\/current"},{"key":"e_1_3_2_30_1","unstructured":"Monthly Index of Medical Specialities. Cresemba (2016). www.mims.co.uk\/drugs\/infections-and-infestations\/fungal-infections\/cresemba"},{"key":"e_1_3_2_31_1","unstructured":"Information Services Division Scotland . Scottish Health Service Costs. R130x Laboratory Services 2014\u201315 (2015). http:\/\/www.isdscotland.org\/Health-Topics\/Finance\/Costs\/Detailed-Tables\/Laboratory.asp.37"},{"key":"e_1_3_2_32_1","unstructured":"Mycology Reference Centre Manchester . Antifungal assays. http:\/\/www.mycologymanchester.org\/antifungal.php"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc2388"},{"key":"e_1_3_2_34_1","unstructured":"Personal Social Services Research Unit . Unit Costs of Health and Social Care 2015 (2015). www.pssru.ac.uk\/project-pages\/unit-costs\/2015\/index.php"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt508"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13114"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/13693780903311944"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30192-X"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2016-0231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:41:48Z","timestamp":1719110508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2016-0231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,13]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.2217\/fmb-2016-0231"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2016-0231","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727302595.793550321","asserted-by":"object"}]},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}